Sanofi slumps despite positive eczema drug readout

Sanofi market value tanks following weak results on eczema drug trials

Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for its experimental inflammatory disease drug amlitelimab disappointed Wall Street. The company said amlitelimab, which it is developing for atopic dermatitis, a severe form of eczema, met all main goals in the Phase III study, showing statistically significant improvements in skin clearance and disease s…

Sanofi slumps despite positive eczema drug readout

Shares in Sanofi have fallen after it reported data from a phase 3 trial of atopic dermatitis drug amlitelimab – even though it met all objectives.

Sanofi shares drop after disappointing trial results

Sanofi shares slid Thursday after the company reported underwhelming results from a closely watched trial in the skin condition atopic dermatitis, part of the French firm’s major push into immunology.  Sanofi said the drug being tested, called amlitelimab, met all primary and key secondary endpoints in the Phase 3 COAST 1 trial, including lowering disease severity and clearing patients’ skin versus placebo. But the results may not stack up again…

Sanofi stock slides on Dupixent successor AD trial

While the Phase III AD trial met all its endpoints, data fell short of Sanofi blockbuster Dupixent.The post Sanofi stock slides on Dupixent successor AD trial appeared first on Clinical Trials Arena.